entinostat entinostat entinostat, also known as sndx-275 and ms-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers. entinostat names preferred iupac name (pyridin-3-yl)methyl (methyl)carbamate other names sndx-275; ms-275 identifiers cas number 209783-80-2 y 3d model (jsmol) interactive image chebi chebi:132082 n chembl chembl27759 n chemspider 4111 n echa infocard 100.158.999 iuphar/bps 7007 kegg d09338 y pubchem cid 4261 unii 1zny4fkk9h y comptox dashboard (epa) dtxsid0041068 inchi inchi=1s/c21h20n4o3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12h,13-14,22h2,(h,24,27)(h,25,26) nkey: invtyaogfagboe-uhfffaoysa-n ninchi=1/c21h20n4o3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12h,13-14,22h2,(h,24,27)(h,25,26)key: invtyaogfagboe-uhfffaoyau smiles c1=cc=c(c(=c1)n)nc(=o)c2=cc=c(c=c2)cnc(=o)occ3=cn=cc=c3 properties chemical formula c21h20n4o3 molar mass 376.4085 g/mol pharmacology atc code l01xh05 (who) except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references entinostat inhibits class i hdac1 and hdac3 with ic50 of 0.51 μm and 1.7 μm, respectively. syndax pharmaceuticals currently holds the rights to entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools.